- Home
- GOVX vs COHN Comparison
GOVX vs COHN Comparison
Compare GOVX & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- COHN
- Stock Information
- Founded
- GOVX 2001
- COHN 1999
- Country
- GOVX United States
- COHN United States
- Employees
- GOVX N/A
- COHN N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- COHN Investment Bankers/Brokers/Service
- Sector
- GOVX Health Care
- COHN Finance
- Exchange
- GOVX Nasdaq
- COHN Nasdaq
- Market Cap
- GOVX 15.5M
- COHN 17.9M
- IPO Year
- GOVX N/A
- COHN N/A
- Fundamental
- Price
- GOVX $0.45
- COHN $9.98
- Analyst Decision
- GOVX Strong Buy
- COHN
- Analyst Count
- GOVX 5
- COHN 0
- Target Price
- GOVX $12.40
- COHN N/A
- AVG Volume (30 Days)
- GOVX 2.4M
- COHN 7.2K
- Earning Date
- GOVX 08-05-2025
- COHN 08-04-2025
- Dividend Yield
- GOVX N/A
- COHN 10.00%
- EPS Growth
- GOVX N/A
- COHN N/A
- EPS
- GOVX N/A
- COHN N/A
- Revenue
- GOVX $5,591,576.00
- COHN $84,171,000.00
- Revenue This Year
- GOVX N/A
- COHN N/A
- Revenue Next Year
- GOVX N/A
- COHN N/A
- P/E Ratio
- GOVX N/A
- COHN N/A
- Revenue Growth
- GOVX N/A
- COHN N/A
- 52 Week Low
- GOVX $0.43
- COHN $6.10
- 52 Week High
- GOVX $11.18
- COHN $11.52
- Technical
- Relative Strength Index (RSI)
- GOVX 28.21
- COHN 76.00
- Support Level
- GOVX $0.43
- COHN $9.50
- Resistance Level
- GOVX $0.98
- COHN $10.03
- Average True Range (ATR)
- GOVX 0.15
- COHN 0.33
- MACD
- GOVX -0.06
- COHN 0.13
- Stochastic Oscillator
- GOVX 2.07
- COHN 89.73
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.